Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

IQ-AI (IQAI)

Intraday
Historical

Price	1.45p on 21-02-2025 at 17:30:02
Change	0.00p 0%
Buy	1.50p
Sell	1.40p
Buy / Sell IQAI Shares

Last Trade:	Unknown 39,759.00 at 1.40p
Day's Volume:	134,047
Last Close:	1.45p
Open:	1.45p
ISIN:	JE00BD4H0R42

Day's Range	1.45p - 1.45p
52wk Range:	0.975p - 2.00p
Market Capitalisation:	£3m
VWAP:	1.408147p
Shares in Issue:	222m

Sector: Health Care and Related Services

Buy/Sell	Volume	Trade Prc	Trade Type	Trade Time
Recent Trades History IQ-AI (IQAI)
Unknown*	39,759	1.40p	OTC Trade	13:58:23 - 21-Feb-25
Unknown*	39,759	1.40p	OTC Trade	13:58:23 - 21-Feb-25
Sell*	39,759	1.40p	Ordinary	13:58:23 - 21-Feb-25
Buy*	10,000	1.4847p	Ordinary	09:53:58 - 21-Feb-25
Buy*	2,088	1.4847p	Ordinary	08:21:03 - 21-Feb-25
Sell*	750	1.40p	SI Trade	08:16:42 - 21-Feb-25
Buy*	308	1.50p	SI Trade	08:16:42 - 21-Feb-25
Sell*	1,250	1.40p	SI Trade	08:16:42 - 21-Feb-25
Buy*	374	1.50p	SI Trade	08:16:42 - 21-Feb-25

Share Price History for IQ-AI
Time period: to
Date	Open	High	Low	Close	Volume

Share News for IQ-AI

IN BRIEF: IQ-AI amends distribution deal with Blackford Analysis

3rd Feb 2025 19:22

IQ-AI Ltd - London-based medical services company - Amends existing distribution agreement with artificial intelligence platform provider Blackford Analysis Ltd. The amendment adds IB Nimble, IB ASL, IB FTB, and IB FTB Express to the agreement, allowing Blackford to also sell these products to their global client base. Acquired by Bayer in early 2023, Blackford operates in the healthcare AI platform and solutions sphere. Read More

IN BRIEF: IQ-AI to take GaM to phase II study, flags AI capabilities

22nd Jan 2025 17:10

IQ-AI Ltd - London-based medical services company - Provides operations update focusing on artificial intelligence. Explains radiology leads the way in Food & Drug Administration approvals for AI-enabled products as the FDA has increased efforts to keep pace with the advancements in AI technology. The company believes its subsidiary, Imaging Biometrics LLC, is in a unique position to lead this transformation for neuro-oncology in 2025 and beyond. Points to the imminent release of the new version of IB Clinic; its FDA-cleared suite of quantitative imaging solutions will include the incorporation of an AI model, which will greatly improve diagnostic accuracy and speed. In addition, notes the first half of 2025 should mark the next release of IB Nimble with the functionality to view IB's AI-generated images and other images within the mobile app. Also, in 2025 we anticipate releasing a new product leveraging arterial spin labelling. Read More

IN BRIEF: Braveheart buys 30% stake in IQ-AI from Braveheart CEO Brown

14th Oct 2024 10:05

IQ-AI Ltd - parent of Wisconsin-based Imaging Biometrics LLC, which provides quantitative imaging platforms and therapeutics for the diagnosis and treatment of patients - AIM-listed technology investor Braveheart Investment Group PLC buys a nearly 30% stake in IQ-AI from Braveheart Chief Executive Officer Trevor Brown. Braveheart buys 45.8 million IQ-AI shares from Brown at 1.1 pence per share, worth GBP503,372, and another 19.7 million shares owned by Brown's children at the same price, worth GBP216,203. The two purchases give Braveheart a 29.5% stake in IQ-AI. Braveheart on Friday says the related-party transaction is approved by its independent shareholders because the IQ-AI business fits Braveheart's investment strategy and the purchase is at "an attractive entry price". Read More

TRADING UPDATES: NetScientific loss narrows; Vinanz ups Bitcoin fleet

16th Aug 2024 20:40

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and Wednesday and not separately reported by Alliance News: Read More

IN BRIEF: IQ-AI subsidiary opens expanded access programme

25th Jun 2024 11:56

IQ-AI Ltd - London-based medical services company - US-based subsidiary Imaging Biometrics LLC says that US Food & Drug Administration has approved an expanded access programme for oral gallium maltolate. This EAP will run in parallel with the current phase 1 clinical trial being conducted at the Medical College of Wisconsin. Explains that "As the phase 1 trial concludes this fall and while the data is being compiled, eligible patients in the US will have the option of participating in the EAP." Read More

FTSE 100 Latest

Value8,659.37

Change-3.60